These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8026028)

  • 1. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration.
    Witt W; Maass B; Baldus B; Hildebrand M; Donner P; Schleuning WD
    Circulation; 1994 Jul; 90(1):421-6. PubMed ID: 8026028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury.
    Reddrop C; Moldrich RX; Beart PM; Farso M; Liberatore GT; Howells DW; Petersen KU; Schleuning WD; Medcalf RL
    Stroke; 2005 Jun; 36(6):1241-6. PubMed ID: 15879331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activators from the saliva of Desmodus rotundus (common vampire bat): unique fibrin specificity.
    Schleuning WD; Alagon A; Boidol W; Bringmann P; Petri T; Krätzschmar J; Haendler B; Langer G; Baldus B; Witt W
    Ann N Y Acad Sci; 1992 Dec; 667():395-403. PubMed ID: 1309059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
    Rapold HJ; Wu ZM; Stassen T; Van de Werf F; Collen D
    Blood; 1990 Oct; 76(8):1558-63. PubMed ID: 2119830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1.
    Dong N; Da Cunha V; Citkowicz A; Wu F; Vincelette J; Larsen B; Wang YX; Ruan C; Dole WP; Morser J; Wu Q; Pan J
    Thromb Haemost; 2004 Nov; 92(5):956-65. PubMed ID: 15543321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration.
    Liberatore GT; Samson A; Bladin C; Schleuning WD; Medcalf RL
    Stroke; 2003 Feb; 34(2):537-43. PubMed ID: 12574572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis.
    Mellott MJ; Stabilito II; Holahan MA; Cuca GC; Wang S; Li P; Barrett JS; Lynch JJ; Gardell SJ
    Arterioscler Thromb; 1992 Feb; 12(2):212-21. PubMed ID: 1371932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA; Gold HK; Yasuda T; Kanke M; Guerrero JL; Fallon JT; Saito T; Collen D
    Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of sustained patency after clot-selective coronary thrombolysis with Hybrid-B, a genetically engineered plasminogen activator with a prolonged biological half-life.
    Weinheimer CJ; James HL; Kalyan NK; Wilhelm J; Lee SG; Hung PP; Sobel BE; Bergmann SR
    Circulation; 1991 Apr; 83(4):1429-36. PubMed ID: 1901531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T; Gold HK; Leinbach RC; Yaoita H; Fallon JT; Guerrero L; Napier MA; Bunting S; Collen D
    Circulation; 1991 Mar; 83(3):1038-47. PubMed ID: 1900221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats.
    Witt W; Baldus B; Bringmann P; Cashion L; Donner P; Schleuning WD
    Blood; 1992 Mar; 79(5):1213-7. PubMed ID: 1536947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR; Ramjit DR; Stabilito II; Lehman D; Lynch JJ; Vlasuk GP
    Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis.
    Sakamoto T; Ogawa H; Yasue H; Oda Y; Kitajima S; Tsumoto K; Mizokami H
    Circulation; 1994 Jul; 90(1):427-32. PubMed ID: 8026029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits.
    Gardell SJ; Ramjit DR; Stabilito II; Fujita T; Lynch JJ; Cuca GC; Jain D; Wang SP; Tung JS; Mark GE
    Circulation; 1991 Jul; 84(1):244-53. PubMed ID: 1905593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of amyloid-beta (1-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator.
    Kruithof EK; Schleuning WD
    Thromb Haemost; 2004 Sep; 92(3):559-67. PubMed ID: 15351852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K; Kloner RA
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
    Chen LY; Nichols WW; Saldeen TG; Mehta JL
    J Cardiovasc Pharmacol; 1996 Feb; 27(2):283-9. PubMed ID: 8720429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA.
    Benedict CR; Refino CJ; Keyt BA; Pakala R; Paoni NF; Thomas GR; Bennett WF
    Circulation; 1995 Nov; 92(10):3032-40. PubMed ID: 7586274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of a mutant tissue-type plasminogen activator, YM866, with a tissue-type plasminogen activator in a canine model of femoral arterial thrombosis.
    Kawasaki T; Kaku S; Sakai Y; Takenaka T
    J Pharm Pharmacol; 1996 Oct; 48(10):1041-8. PubMed ID: 8953506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.